

Dana C Miskulin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7373265/publications.pdf>

Version: 2024-02-01

39
papers

1,273
citations

394421

19
h-index

361022

35
g-index

39
all docs

39
docs citations

39
times ranked

1673
citing authors

#	ARTICLE	IF	CITATIONS
1	Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2022, 80, 309-318.	1.9	5
2	Assessing Risk of Progression in ADPKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 134-136.	4.5	3
3	Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants. <i>Kidney360</i> , 2021, 2, 795-808.	2.1	10
4	COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider. <i>American Journal of Kidney Diseases</i> , 2021, 77, 748-756.e1.	1.9	181
5	mRNA COVID-19 Vaccine for People with Kidney Failure: Hope but Prudence Warranted. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 996-998.	4.5	4
6	Comparison of Dialysis Unit and Home Blood Pressures: An Observational Cohort Study. <i>American Journal of Kidney Diseases</i> , 2021, 78, 640-648.	1.9	4
7	Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). <i>Kidney International</i> , 2021, 100, 684-696.	5.2	48
8	Drug Selection for Treating Hypertension in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1084-1086.	4.5	1
9	We use our judgment and do the best we can. <i>Seminars in Dialysis</i> , 2020, 33, 185-186.	1.3	0
10	Multidisciplinary Medication Therapy Management and Hospital Readmission in Patients Undergoing Maintenance Dialysis: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 13-21.	1.9	22
11	Transfers to Hemodialysis Among US Patients Initiating Renal Replacement Therapy With Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 2019, 74, 620-628.	1.9	34
12	The TiME Trial: A Fully Embedded, Cluster-Randomized, Pragmatic Trial of Hemodialysis Session Duration. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 890-903.	6.1	38
13	Influenza in dialysis patients. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 607-614.	2.0	2
14	Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2018, 3, 619-624.	0.8	7
15	Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. <i>American Journal of Kidney Diseases</i> , 2018, 71, 666-676.	1.9	30
16	BP in Dialysis: Results of a Pilot Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 307-316.	6.1	49
17	ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. <i>American Journal of Kidney Diseases</i> , 2018, 71, 294-296.	1.9	5
18	High-Dose Seasonal Influenza Vaccine in Patients Undergoing Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1703-1711.	4.5	22

#	ARTICLE	IF	CITATIONS
19	In-Center Hemodialysis: Time for a Paradigm Shift. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2452-2454.	6.1	4
20	A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Nephrology</i> , 2018, 47, 352-360.	3.1	47
21	Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2017, 2, 442-450.	0.8	92
22	Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain. <i>Seminars in Dialysis</i> , 2017, 30, 203-212.	1.3	19
23	A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2017, 2, 451-460.	0.8	19
24	Infection Monitoring in Dialysis Units: A Plea for "Cleaner" Data. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1038-1039.	4.5	2
25	Vascular imaging for hemodialysis vascular access planning. <i>Hemodialysis International</i> , 2017, 21, 490-497.	0.9	4
26	Peripherally Inserted Central Catheters and Hemodialysis Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1434-1440.	4.5	29
27	Comparison of Prescribed and Measured Dialysate Sodium: A Quality Improvement Project. <i>American Journal of Kidney Diseases</i> , 2016, 67, 439-445.	1.9	27
28	Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1801-1810.	6.1	56
29	Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). <i>American Journal of Kidney Diseases</i> , 2015, 66, 583-590.	1.9	21
30	Satisfaction with Care of Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1428-1434.	4.5	10
31	Closeout of the HALT-PKD trials. <i>Contemporary Clinical Trials</i> , 2015, 44, 48-55.	1.8	1
32	Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 155-164.e6.	4.4	90
33	Intravenous Iron Exposure and Mortality in Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1930-1939.	4.5	61
34	Health-Related Quality of Life in Patients With Autosomal Dominant Polycystic Kidney Disease and CKD Stages 1-4: A Cross-sectional Study. <i>American Journal of Kidney Diseases</i> , 2014, 63, 214-226.	1.9	93
35	Trends in anemia management in US hemodialysis patients 2004-2010. <i>BMC Nephrology</i> , 2013, 14, 264.	1.8	18
36	Computerized Decision Support for EPO Dosing in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2009, 54, 1081-1088.	1.9	35

#	ARTICLE	IF	CITATIONS
37	Hypertension in Hemodialysis Patients: The Role of Antihypertensive Medications. American Journal of Kidney Diseases, 2009, 54, 996-999.	1.9	2
38	Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrology Dialysis Transplantation, 2004, 19, 413-420.	0.7	91
39	Comorbidity and its change predict survival in incident dialysis patients. American Journal of Kidney Diseases, 2003, 41, 149-161.	1.9	87